Drug
Capecitabine
Capecitabine: highest development phase Phase 3, developed by Eli Lilly, Gilead Sciences, Menarini and others. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eli Lilly, Gilead Sciences, Menarini
Trials
| Drug | Phase | Indication |
|---|---|---|
| Capecitabine NCT04595565 | Phase 3 | HER2-negative Breast Cancer |
| Capecitabine NCT07340567 | Phase 3 | Colorectal Cancer |
| Capecitabine NCT00496587 | Phase 2 | Renal Cell Carcinoma |
| Capecitabine NCT00216073 | Phase 2 | Metastatic Breast Cancer |
| Capecitabine NCT07222215 | Phase 2 | Estrogen-receptor-positive Breast Cancer |
| Capecitabine NCT02085005 | Phase 2 | Colorectal Cancer Metastatic |
| Capecitabine NCT04703101 | Phase 1 | Locally Advanced Rectal Carcinoma |
| Capecitabine NCT05108428 | Phase 1 | Rectal Adenocarcinoma |
Latest
No recent events.
Follow Capecitabine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.